DK158784A - Mucoid exopolysaccharidvaccine mod pseudomonas aeruginosa - Google Patents

Mucoid exopolysaccharidvaccine mod pseudomonas aeruginosa Download PDF

Info

Publication number
DK158784A
DK158784A DK158784A DK158784A DK158784A DK 158784 A DK158784 A DK 158784A DK 158784 A DK158784 A DK 158784A DK 158784 A DK158784 A DK 158784A DK 158784 A DK158784 A DK 158784A
Authority
DK
Denmark
Prior art keywords
pseudomonas aeruginosa
mucoid
exopolysaccharid
vaccine against
against pseudomonas
Prior art date
Application number
DK158784A
Other languages
Danish (da)
English (en)
Other versions
DK158784D0 (da
Inventor
Gerald B Pier
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of DK158784D0 publication Critical patent/DK158784D0/da
Publication of DK158784A publication Critical patent/DK158784A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/38—Pseudomonas
    • C12R2001/385—Pseudomonas aeruginosa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/874—Pseudomonas
    • Y10S435/875—Pseudomonas aeruginosa

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK158784A 1983-03-23 1984-03-19 Mucoid exopolysaccharidvaccine mod pseudomonas aeruginosa DK158784A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/477,958 US4578458A (en) 1983-03-23 1983-03-23 Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa

Publications (2)

Publication Number Publication Date
DK158784D0 DK158784D0 (da) 1984-03-19
DK158784A true DK158784A (da) 1984-09-24

Family

ID=23898005

Family Applications (1)

Application Number Title Priority Date Filing Date
DK158784A DK158784A (da) 1983-03-23 1984-03-19 Mucoid exopolysaccharidvaccine mod pseudomonas aeruginosa

Country Status (7)

Country Link
US (1) US4578458A (de)
EP (1) EP0120532B1 (de)
AT (1) ATE52695T1 (de)
AU (1) AU571495B2 (de)
CA (1) CA1226543A (de)
DE (1) DE3482241D1 (de)
DK (1) DK158784A (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60248625A (ja) * 1984-05-25 1985-12-09 Mitsui Toatsu Chem Inc 抗緑膿菌モノクロ−ナル抗体、その製法ならびに用途
AT384032B (de) * 1985-01-14 1987-09-25 Immuno Ag Verfahren zur herstellung von polydispersen nativen pseudomonas-flagella(h)-antigenen (fag)
US4693891A (en) * 1985-09-09 1987-09-15 Miles Laboratories, Inc. Vaccine for Pseudomonas aeruginosa
US5114712A (en) * 1985-11-14 1992-05-19 Mitsui Toatsu Chemicals, Inc. Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent for protecting Pseudomonas aeruginosa infection
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US5169840A (en) * 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
US5233024A (en) * 1991-04-09 1993-08-03 The Brigham & Women's Hospital Anti-idiotypic monoclonal antibodies for mucoid pseudomonas aeruginosa, their preparation and use
DE4204012A1 (de) * 1992-02-12 1993-08-19 Ulrich Prof Dr Zimmermann Mitogenfreie substanz, deren herstellung und verwendung
WO1994008617A1 (en) * 1992-10-16 1994-04-28 Brigham And Women's Hospital, Inc. O-derivatized alginic acid antigens
US5633234A (en) * 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
KR100397793B1 (ko) 2000-07-28 2003-09-13 삼성전자주식회사 느릅나무로부터 분리된 신규의 미생물 및 그를 이용한항암 면역활성의 세포밖 당화합물의 제조방법
US7119172B2 (en) 2001-05-21 2006-10-10 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
US6962813B2 (en) * 2001-05-21 2005-11-08 The Brigham And Women's Hospital, Inc. P. aeruginosa mucoid exopolysaccharide specific binding peptides
NZ539153A (en) 2002-11-12 2006-11-30 Brigham & Womens Hospital Polysaccharide vaccine for staphylococcal infections
EP1583517B1 (de) * 2002-11-12 2019-06-12 The Brigham And Women's Hospital, Inc. Verfahren und produkte zur behandlung von infektionen mit staphylokokken
CA2508536A1 (en) * 2002-12-04 2004-06-17 Technologies Biolactis Inc. An exopolysaccharides delivery system for active molecules
AU2005236068C1 (en) 2004-04-21 2012-08-30 Beth Israel Deaconess Medical Center, Inc. Poly-N-acetyl glucosamine (PNAG/DPNAG)-binding peptides and methods of use thereof
AU2005286694A1 (en) * 2004-09-21 2006-03-30 The Brigham And Women's Hospital, Inc. Methods and compositions relating to mannuronic acid specific binding peptides
CA2646539A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
EP3312158A1 (de) 2008-07-21 2018-04-25 The Brigham and Women's Hospital, Inc. Verfahren und zusammensetzungen in verbindung mit synthetischen beta-1,6 glucosamin-oligosacchariden

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2290219A1 (fr) * 1974-11-05 1976-06-04 Pasteur Institut Principe actif de vaccin antipyocyanique
US4285936A (en) * 1979-12-10 1981-08-25 The United States Of America As Represented By The Secretary Of The Army Method for producing a vaccine against bacterial infections caused by pseudomonas aeruginosa

Also Published As

Publication number Publication date
AU571495B2 (en) 1988-04-21
CA1226543A (en) 1987-09-08
ATE52695T1 (de) 1990-06-15
EP0120532B1 (de) 1990-05-16
DE3482241D1 (de) 1990-06-21
AU2548184A (en) 1984-09-27
EP0120532A2 (de) 1984-10-03
US4578458A (en) 1986-03-25
DK158784D0 (da) 1984-03-19
EP0120532A3 (en) 1985-12-18

Similar Documents

Publication Publication Date Title
DK158784A (da) Mucoid exopolysaccharidvaccine mod pseudomonas aeruginosa
ES516354A0 (es) "un metodo para aislar una bacteria del genero pseudomonas".
DK39991A (da) Oral immunisering
SE8404707D0 (sv) Komposition innehallande pyridinlosligt extrakt och raffinerat detoxifierat endotoxin samt anvendning derav
AU6750181A (en) Vaccinal complex containing a specific antigen and vaccine containing it
ATE165515T1 (de) Immuntoleranzinduzierendes agens
PL318930A1 (en) Mutant enterotoxin effective as a non-toxic adjutant
ES2125901T3 (es) Empleo de lipasas para la obtencion de medicamentos.
FI913275A0 (fi) Foerfarande foer foerbaettring av sjukdomsmottstaondskraft.
AU2152988A (en) Intranasal vaccination of horses with inactivated microorganisms or antigenic material
EP0306524A4 (de) Von antikörpern, die unter verwendung eines eine beschränkte anzahl von antigenen präsentierenden pathogenen agens oder eines seiner derivate hergestellt worden sind, erkannte antigene determinanten.
EP0245433A4 (de) Wichtigstes protein von neisseria gonorrhöe mit eisenregelung und dessen verwendung.
FI920356A0 (fi) En biologisk preparation samt dess anvaendning.
FR2618910B1 (fr) Methode et dispositif pour ameliorer le coefficient de transmission aux formations geologiques de l'energie creee par une source sismique de puits
LU90378I2 (fr) Tetravac
DK0427462T3 (da) Fremgangsmåde
EP0642333A4 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion.
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
EP0090660A3 (de) Neisseria Gonorrhöe Vakzin
KR890700832A (ko) 그람 음성균의 항원 결정기와 결합하는 사람 단일클론성 항체
EP0189841A3 (en) Enzymatic detection of bacterial capsular polysaccharide antigens
JPS5781416A (en) Cilia of pseudomonas aeruginosa and method of using cilia as vaccine of pseudomonas aeruginosa infections
Szegli et al. Gram-negative bacterial infection and acute knee joint arthritis.
EP0587765A4 (de) Induktion der immunantwort gegen das tetanustoxin durch verarbeitung von mycobakterien, die das tetanustoxin oder fragmente davon exprimieren.
Sokalska et al. Effect of Immunization With Extracellular Slime From Pseudomonas aeruginosa on Experimental Infection in Mice.

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Free format text: CA 1997 00029, 970716

CTFG Supplementary protection certificate (spc) issued

Free format text: CA 1997 00029, 970716, EXPIRES: 20001108

PUP Patent expired
AHS Application shelved for other reasons than non-payment